Top Medical Companies To Buy Right Now

With shares of General Electric (NYSE:GE) trading around $26, is GE an OUTPERFORM, WAIT AND SEE, or STAY AWAY? Let�� analyze the stock with the relevant sections of our CHEAT SHEET investing framework:

T = Trends for a Stock’s Movement

General Electric is a diversified industrial, technology, and financial services company that operates worldwide. The products and services of the company range from aircraft engines, power generation, water processing, and household appliances to medical imaging, business and consumer financing, and industrial products. General Electric�� segments are Energy Infrastructure, Aviation, Healthcare, Transportation, Home & Business Solutions, and GE Capital. General Electric is a leading provider of a wide range of products and many are essential in daily lives of consumers and companies around the world.

General Electric announced that it will close an electrical capacitor facility in northern New York that employs around 200 persons. The company advised workers that it will follow through on plans announced in September to shut its plant 45 miles north of Albany, and transfer operations to an existing manufacturing site in Clearwater, Florida. The plant located close to the Hudson River will not close prior to September 2014.

Top Consumer Stocks To Own Right Now: Tekmira Pharmaceuticals Corp (TKMR)

Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing ribonucleic acid (RNA) interference (RNAi) therapeutics and providing its lipid nanoparticle (LNP) delivery technology to pharmaceutical partners. On March 1, 2012, it announced that the Company had secured a license from Alnylam to develop TKMALDH2, an RNAi therapeutic that utilizes Tekmira's LNP for the treatment of Alcohol Dependence (AD). Its lead oncology product candidate, TKM-PLK1, targets PLK1, a protein involved in tumor cell proliferation and a validated oncology target. On February 8, 2012, it announced that Phase I clinical trial for TKM-Ebola had been initiated. The Phase 1 TKM-Ebola clinical trial is a placebo-controlled, single-blind, single-ascending dose study with additional multiple-ascending dose cohorts in healthy human volunteers. In the field of RNAi therapeutics, the Company has licensed its LNP delivery technology to Alnylam Pharmaceuticals, Inc. and Merck & Co., Inc. Advisors' Opinion:

• [By Lisa Levin]

  Tekmira Pharmaceuticals (NASDAQ: TKMR) shares climbed 34.11% to $13.25. The volume of Tekmira Pharmaceuticals shares traded was 2187% higher than normal. Tekmira signed a development agreement with Monsanto (NYSE: MON) on delivery technology for agricultural applications.

• [By Markus Aarnio]

  Companies working on chemically synthesized siRNAs include Merck (MRK), through its subsidiary Sirna Therapeutics, Inc., Novartis (NVS), Takeda (TKPHF.PK), Kyowa Hakko Kirin, Marina Biotech, Inc., Arrowhead and its subsidiary, Calando, Quark, Silence Therapeutics plc, Tekmira (TKMR), Sylentis and Dicerna Pharmaceuticals, Inc.

Top Medical Companies To Buy Right Now: HeartWare International Inc (HTWR)

Heartware International, Inc. (HeartWare), incorporated on June 25, 2010, develops and manufactures small implantable heart pumps, or ventricular assist devices, for the treatment of advanced heart failure. The HeartWare Ventricular Assist System (the HeartWare System), which includes a ventricular assist device (VAD), or blood pump, patient accessories and surgical tools, is designed to provide circulatory support for patients in the advanced stage of heart failure. The core of the HeartWare System is a continuous flow blood pump, the HVAD Pump, which is a full-output device capable of pumping up to 10 liters of blood per minute. The HeartWare System is designed to be implanted adjacent to the heart, avoiding the abdominal surgery generally required to implant similar devices. In August 2012, it acquired World Heart Corporation. As of December 31, 2012, the HeartWare System has been implanted outside of the United States at approximately 168 health care sites in 28 countries. In December 2013, HeartWare International Inc acquired CircuLite, Inc.

Proprietary Pump Technology

The HeartWare System is full-output centrifugal pump designed to be implanted in the chest, directly adjacent to the heart. At the core of the Company�� technology platform is its hybrid system for suspending the impeller, which is the only moving part within the pump. The impeller is suspended within the pump housing by the opposing forces of passive magnets and hydrodynamic thrust generated by the pump impeller, which circulates a cushion of

blood. Once power is applied to the device and the impeller begins to rotate, there are no points of mechanical contact within the pump, thus providing a completely wearless pumping system.

The HeartWare System

The HeartWare System consists of the HVAD Pump, a small, permanently implantable VAD, patient accessories and surgical tools. The HVAD Pump is capable of generating up to 10 liters of blood flow per minute. With a displaced v! olume of only 50 cubic centimeters and a mass of 140 grams, the HVAD Pump is the only full-output pump implantable in the pericardial space, directly adjacent to the heart. It is also the only pump designed to be implanted above the diaphragm in all eligible patients.

The HeartWare MVAD

The miniaturized ventricular assist device (MVAD) is a miniaturized blood pump intended for chronic heart failure patients. The device is a full-output axial flow pump with a fully suspended rotor and a displacement volume approximately one-third that of the HVAD Pump.

The Company competes with Thoratec Corporation, Jarvik Heart, MicroMed Technology, Inc, Berlin Heart AG, Terumo Heart, Inc., Sunshine Heart, Inc and CircuLite, Inc., Evaheart Medical USA, Inc.

Advisors' Opinion:

• [By Todd Campbell]

  Competing for heart pump market share
  Abiomed's products provide circulatory support for up to six hours and are designed for use in cardiac cath labs or during heart surgery, but competitors Thoratec (NASDAQ: THOR  ) and Heartware (NASDAQ: HTWR  ) target the intermediate- and long-term-use market instead.

• [By Maria Armental var popups = dojo.query(".socialByline .popC"); popups.forEach]

  HeartWare International Inc.(HTWR) said it received a warning letter from the U.S. Food and Drug Administration, citing concerns about procedures for validating device design and other issues.

• [By Lauren Pollock]

  Medical device company HeartWare International Inc.(HTWR) issued a revenue forecast that fell short of market expectations.

  Intrepid Potash Inc.(IPI), the largest potash producer in the U.S., plans to cut its workforce by 7% and cut executive compensation as part of a plan to trim costs in reaction to weaker prices for the fertilizer ingredient.

Top Medical Companies To Buy Right Now: Cambridge Heart Inc (CAMH)

Cambridge Heart, Inc., incorporated on January 16, 1990, is engaged in the research, development and commercialization of products for the non-invasive diagnosis of cardiac disease. The Company's products incorporate its technology for the measurement of Microvolt T-Wave Alternans (MTWA). The MTWA Test is conducted by elevating the patient's heart rate through exercise as performed on a treadmill similar to a stress test, pharmacologic agents, or pacing with electrical pulses.

The Company's products, including its first generation HearTwave System and second generation HearTwave II System, CH 2000 Cardiac Stress Test System, MTWA original equipment manufacturer (OEM) Module (MTWA Module) and Micro-V Alternans Sensors have received 510(k) clearance from the United States Food and Drug Administration (FDA) for sale in the United States. The Company's products have also received the Conformite Europeenne (CE) mark for sale in Europe. The Company's first generation HearTwave System, CH 2000 Cardiac Stress Test System and the HearTwave II System have been approved for sale by the Japanese Ministry of Health Labor and Welfare.

The Company's 510(k) clearance allows the Company's MTWA Test to be used to test patients with known, suspected, or at risk of ventricular tachyarrhythmia and/or sudden cardiac arrest, and allows the claim that its MTWA Test is predictive of those events. The MTWA Module is designed to work with existing cardiac stress test platforms distributed by other manufacturers as an add-on module to enable MTWA testing to be performed using the Company's Micro-V Alternans Sensors.

The Company's HearTwave II System, which has replaced the Company's original HearTwave System, is used to perform both MTWA testing and standard cardiac stress testing. In addition to MTWA measurement, the Company's HearTwave II System is a cardiac diagnostic system designed to support a range of customized protocols for the conduct of cardiac exercise stress testing. The Comp! any's Micro-V Alternans Sensors are single patient use, multi-segment electrodes. The Company's CH2000 is a cardiac diagnostic system designed to support a range of customized protocols for the conduct and measurement of cardiac exercise stress testing.

The Company competes with GE Medical Systems.

Advisors' Opinion:

• [By Peter Graham]

  Last Friday, small cap stocks Cambridge Heart, Inc (OTCMKTS: CAMH), Abby Inc (OTCMKTS: ABBY) and Grillit Inc (OTCMKTS: GRLT) surged 176.92%, 71.2% and 24.07%, respectively. Of course, that was last week and today is a new trading week. So what should investors and traders alike be prepared for this week with these three small caps? Here is a closer look to help you decide on an investing or trading strategy:

  Cambridge Heart, Inc (OTCMKTS: CAMH) Recently Changed Its Board

  Small cap Cambridge Heart, Inc is a healthcare company engaged in the research, development and commercialization of products for the non-invasive diagnosis of cardiac disease. On Friday, Cambridge Heart, Inc surged 176.92% to $0.018 for a market cap of $1.80 million plus CAMH is up 20% since the start of the year and down 86.1% over the past five years according to Google Finance.

Top Medical Companies To Buy Right Now: BIOLASE Inc (BIOL)

BIOLASE, Inc., formerly BIOLASE Technology, Inc., incorporated in 1987, is a medical technology company that develops, manufactures and markets lasers, and markets and distributes dental imaging equipment and other related products designed for applications and procedures in dentistry and medicine. The Company's dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other specialists to perform a range of dental procedures, including cosmetic and complex surgical applications in a minimally invasive manner. The Company also manufactures and sells disposable products and accessories for its laser systems. The Company's Waterlase and Diode systems use disposable laser tips of differing sizes and shapes depending on the procedures being performed. The Company also markets flexible fibers and hands pieces. For the Company's ezlase system, the Company sells tooth whitening gel kits. In April 2012, it purchased 159 Waterlase MD Turbo laser systems from Henry Schein, Inc.

The Company's Waterlase Dentistry consists of two product lines Waterlase systems and Diode systems. In July 2011, the Company introduced the Biolase DaVinci Imaging line of imaging products, which enabled the Company to offer digital diagnostic solutions to complement the minimally invasive dental treatment solutions offered by its Waterlase and Diode dental systems. The Company added the distribution of the NewTom cone beam computed tomography (CBCT), to its imaging product line. The integration of the Company's laser products with imaging offers dental professionals the Total Technology Solution, which provides imaging capabilities for early diagnosis and minimally invasive treatment with its Waterlase iPlus and iLase laser technologies.

The Company's all-tissueWaterlase dental laser systems consist of the Waterlase iPlus, the Waterlase MD Turbo, and the Waterlase MDX 300 and 450, both introduced in February 2012. Each of these systems is designed around the Company's yttrium scandi! um gallium garnet (YSGG) laser technology that refers to the laser crystal used in the Waterlase system, which contains the elements erbium, chromium and yttrium, scandium, gallium and garnet. This crystal laser produces energy with specific absorption and tissue interaction characteristics optimized for dental applications. HydroPhotonics refers to the interaction of YSGG lasers with water to produce energy to cut tissue. It is minimally invasive and can cut hard tissue, such as bone and teeth, and soft tissue, such as gums or skin, without the heat, vibration, or pressure associated with traditional dental treatments. By eliminating heat, vibration, and pressure, the Company's Waterlase systems eliminate the need for anesthesia.

The Waterlase systems incorporate an ergonomic handpiece and a control panel located on the front of the system with precise preset functionality to control the mix of laser energy, air, and water, as well as the pulse rate. The Waterlase iPlus incorporates the iLase wireless diode laser that can be utilized for unexpected soft-tissue cases in an adjacent treatment room, controlling bleeding, and temporary pain relief.

The Company's Diode laser systems in dentistry consist of the ezlase and iLase, semiconductor diode lasers to perform soft tissue, hygiene, cosmetic procedures, teeth whitening, and temporary pain relief. The Company's ezlase system serves the markets of general, cosmetic, orthodontic and hygienic procedures. It features a pulse mode, ComfortPulse, which allows the tissue to cool between pulses and reduces the need for anesthesia for many common procedures. Other features include a wireless foot pedal control, disposable single-use tips, color touch screen activation with up to fifteen procedure based pre-sets, a whitening hand piece, a rechargeable battery pack, and a wall mount.

The Company's imaging systems include the Company's design and distribution of extra-oral and intra-oral dental digital imaging devices. The Co! mpany's e! xpansion into digital imaging systems enables the Company to offer diagnostic solutions to complement the minimally invasive dental treatment solutions offered by the Company's Waterlase and Diode dental systems. The Company provides both high-precision intuitive diagnosis and treatment planning solutions. The Company's Biolase DaVinci Imaging systems include the D3D, a three dimensional (3D) CBCT, and portable digital x-ray and intra-oral camera devices.

The NewTom VGi is a small-footprint CBCT system that offers medical grade imaging technology. In addition to producing up to image resolution with medical grade rotating anode technology, SafeBeam technology automatically adjusts radiation dosage. The Company's Medical systems include the Diolase 10 Diode Laser. As of December 31, 2011, the Company has sold approximately 8,700 Waterlase systems, including over 4,700 Waterlase MD and iPlus systems, and more than 19,000 laser systems in total in over 60 countries. As of decembe31, 2011, the Company�� other products under development address ophthalmology, dermatology, orthopedics, podiatry, and other medical and consumer markets.

The Company competes with Lares Dental Research, Fotona d.d., KaVo Dental GmbH, Lambda SpA, J Morita Manufacturing Corp., Syneron Medical Ltd, Deka Laser Technologies, Inc. Ivoclar Vivadent, Inc., Dentsply, Inc., Royal Philips Electronics and Sirona Dental Systems, Inc.

Advisors' Opinion:

• [By Roberto Pedone]

  Another under-$10 stock that's starting to trend within range of triggering a big breakout trade is Biolase (BIOL), which develops, manufactures and markets laser systems for dental and medical applications. This stock has been trending modestly higher in 2013, with shares up by 15.9%.

  If you take a look at the chart for Biolase, you'll notice that this stock has been uptrending strong for the last month and change, with shares pushing higher from its low of $1.47 to its recent high of $2.25 a share. During that uptrend, shares of BIOL have been mostly making higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of BIOL within range of triggering a big breakout trade.

  Traders should now look for long-biased trades in BIOL if it manages to break out above some near-term overhead resistance levels at $2.25 to $2.50 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 311,533 shares. If that breakout hits soon, then BIOL will set up to re-test or possibly take out its next major overhead resistance levels at its 200-day moving average of $3.07 a share to $3.50 or $3.70 a share.

  Traders can look to buy BIOL off weakness to anticipate that breakout and simply use a stop that sits right below its 50-day moving average of $1.85 a share. One can also buy BIOL off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.